Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs.

BACKGROUND Because interactions with warfarin represent a serious risk to patients, drug information sources used by clinicians should contain accurate, timely, and practical drug interaction information. OBJECTIVE The aim of this study was to assess the information regarding warfarin interactions that is included in the official labeling of prescription products that interact with warfarin. METHODS We examined the official labeling information approved by the US Food and Drug Administration for the 50 drugs, biologics, and drug classes that were commonly identified by 3 drug information compendia--Clinical Pharmacology, ePocrates(®), and Micromedex(®)--and the warfarin US prescribing information (PI) as having an interaction with warfarin. The PI of each product was assessed for possible mention of an interaction with warfarin. The data were collected and tabulated by 1 investigator. A clinical investigator evaluated the data for accuracy and consistency. Unresolved issues were discussed with a third investigator and decided by consensus. The interaction listings were compared to determine similarities, differences, and inconsistencies and analyzed by 5 investigators. RESULTS Of the labeling for 73 products evaluated, 62 (85%) included mention of an interaction with warfarin. Those failing to mention the warfarin interaction were for older generic drugs or influenza vaccine. Among the labels listing an interaction with warfarin, the location of the information, the terminology used, and the inclusion of evidence for the interaction was inconsistent . When considering the PI for all 73 products, Fleiss' kappa coefficient (κ = 0.467) suggested moderate concordance according to the method of Landis and Koch. CONCLUSION This assessment of official US product labeling for 50 drugs, biologics, and drug classes known to interact with warfarin, comprising 73 distinct agents, found that 15% failed to mention the interaction, even though the interaction was mentioned in the warfarin labeling.

[1]  G. Gabb.  Fatal outcome of interaction between warfarin and a nonsteroidal anti‐inflammatory drug , 1996, The Medical journal of Australia.

[2]  J. Fleiss.  Measuring nominal scale agreement among many raters. , 1971 .

[3]  A. Vitry,et al.  Comparative assessment of four drug interaction compendia. , 2007, British journal of clinical pharmacology.

[4]  Amy J Grizzle,et al.  Concordance of severity ratings provided in four drug interaction compendia. , 2004, Journal of the American Pharmacists Association : JAPhA.

[5]  J. Lightwood,et al.  Black Box Warning Contraindicated Comedications: Concordance Among Three Major Drug Interaction Screening Programs , 2010, The Annals of pharmacotherapy.

[6]  A. Wittkowsky,et al.  Frequency of Concurrent Use of Warfarin with Potentially Interacting Drugs , 2004, Pharmacotherapy.

[7]  Nancy Verzier,et al.  The safety of warfarin therapy in the nursing home setting. , 2007, The American journal of medicine.

[8]  Colin Simpson,et al.  The Potential for Interaction between Warfarin and Coprescribed Medication , 2008, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[9]  Walter E. Haefeli,et al.  Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature , 2005, European Journal of Clinical Pharmacology.

[10]  Mark Crowther,et al.  Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.

[11]  D. Malone,et al.  Warfarin Interactions With Substances Listed in Drug Information Compendia and in the FDA‐Approved Label for Warfarin Sodium , 2009, Clinical pharmacology and therapeutics.

[12]  E. Olvey,et al.  Comparison of Critical Drug–Drug Interaction Listings: The Department of Veterans Affairs Medical System and Standard Reference Compendia , 2010, Clinical pharmacology and therapeutics.

[13]  Yu Ko,et al.  Clinically Significant Drug–Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: Profiling and Comparison of Two Drug Compendia , 2008, The Annals of pharmacotherapy.

[14]  H. Maibach,et al.  Lack of Drug Interaction Conformity in Commonly Used Drug Compendia for Selected At-Risk Dermatologic Drugs , 2005, American journal of clinical dermatology.

[15]  Robert J. Valuck,et al.  Disagreement among drug compendia on inclusion and ratings of drug-drug Interactions , 2000 .

[16]  A. Papaioannou,et al.  Quality of anticoagulation and use of warfarin-interacting medications in long-term care: A chart review , 2008, BMC geriatrics.

[17]  Utilization review of concomitant use of potentially interacting drugs in Thai patients using warfarin therapy , 2007, Pharmacoepidemiology and drug safety.

[18]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[19]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[20]  G. Trifirò,et al.  Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. , 2006, British journal of clinical pharmacology.

[21]  E. Ellerbeck,et al.  The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation , 2002, Pharmacoepidemiology and drug safety.

[22]  Daniel C. Malone,et al.  Erratum: Comparison of critical drug-drug interaction listings: The department of veterans affairs medical system and standard reference compendia (Clinical Pharmacology and Therapeutics (2009) 87 (48-51) doi:10.1038/clpt.2009. 198) , 2010 .